Karo Bio is a pharmaceutical company that develops innovative drugs for key medical needs.
Karo Bio aims to create a balance between preclinical projects and products and projects closer to market.
Karo Bio’s vision is to become a pharmaceutical company with sustainable profitability, commercial products and a competitive project portfolio that combines collaborative projects with its own development projects.
Karo Bio focuses on nuclear receptors as target proteins for the development of new drugs. Our development projects are within the indications neuropsychiatry, inflammation, autoimmune diseases and cancer.
Notice for the extraordinary general meeting on August 7.
Karo Bio presents the report in an audiocast. The presentation is in Swedish.